Bartsch L, Fiebig N, Strauss S, Angermaier A, Smith C, Reuter U
J Clin Med. 2024; 13(14).
PMID: 39064279
PMC: 11278222.
DOI: 10.3390/jcm13144239.
Gomez-Sanchez E, Hernandez-Gomez A, Guzman-Flores J, Alonso-Castro A, Serafin-Higuera N, Balderas-Pena L
Clin Pract. 2024; 14(2):461-472.
PMID: 38525714
PMC: 10961807.
DOI: 10.3390/clinpract14020035.
Overeem L, Peikert A, Hofacker M, Kamm K, Ruscheweyh R, Gendolla A
Cephalalgia. 2021; 42(4-5):291-301.
PMID: 34644203
PMC: 8988456.
DOI: 10.1177/03331024211048765.
Bryson A
BMJ Neurol Open. 2021; 3(2):e000193.
PMID: 34632387
PMC: 8477251.
DOI: 10.1136/bmjno-2021-000193.
Tepper S, Ashina M, Reuter U, Hallstrom Y, Broessner G, Bonner J
J Headache Pain. 2021; 22(1):81.
PMID: 34301173
PMC: 8299690.
DOI: 10.1186/s10194-021-01292-w.
The Efficacy of Percutaneous Patent Foramen Ovale Closure on Migraine: a Meta-Analysis of Randomized Controlled Trials and Observational Studies.
Zhang Q, Lu J, Yan M, Hu X, Qin Y, Wang D
Biomed Res Int. 2021; 2021:6643266.
PMID: 33748272
PMC: 7954613.
DOI: 10.1155/2021/6643266.
Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation.
Yiangou A, Mitchell J, Fisher C, Edwards J, Vijay V, Alimajstorovic Z
Headache. 2020; 61(1):157-169.
PMID: 33316102
PMC: 7898289.
DOI: 10.1111/head.14026.
Efficacy of patent foramen ovale closure for treating migraine: a prospective follow-up study.
Qi Y, Zhang Y, Luo X, Cheng G, Du Y, Liu R
J Investig Med. 2020; 69(1):7-12.
PMID: 32928904
PMC: 7803887.
DOI: 10.1136/jim-2020-001323.
Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
Kokoti L, Drellia K, Papadopoulos D, Mitsikostas D
J Neurol. 2020; 267(4):1158-1170.
PMID: 31919565
DOI: 10.1007/s00415-019-09673-7.
Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
Ruff D, Ford J, Tockhorn-Heidenreich A, Stauffer V, Govindan S, Aurora S
Eur J Neurol. 2019; 27(4):609-618.
PMID: 31692188
PMC: 7155018.
DOI: 10.1111/ene.14114.
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y
Headache. 2019; 59(10):1731-1742.
PMID: 31612482
PMC: 6900095.
DOI: 10.1111/head.13652.
Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia.
Crespi J, Bratbak D, Dodick D, Matharu M, Jamtoy K, Tronvik E
Headache. 2019; 59(8):1229-1239.
PMID: 31342515
PMC: 6771650.
DOI: 10.1111/head.13608.
The safety and preventive effects of a supraorbital transcutaneous stimulator in Japanese migraine patients.
Danno D, Iigaya M, Imai N, Igarashi H, Takeshima T
Sci Rep. 2019; 9(1):9900.
PMID: 31289281
PMC: 6617446.
DOI: 10.1038/s41598-019-46044-8.
Manual therapy for chronic migraine: a pragmatic randomised controlled trial study protocol.
Odell J, Clark C, Hunnisett A, Ahmed O, Branney J
Chiropr Man Therap. 2019; 27:11.
PMID: 30962877
PMC: 6436233.
DOI: 10.1186/s12998-019-0232-4.
Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
Stauffer V, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora S
Headache. 2019; 59(6):834-847.
PMID: 30942898
PMC: 6593785.
DOI: 10.1111/head.13508.
Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
Forderreuther S, Zhang Q, Stauffer V, Aurora S, Lainez M
J Headache Pain. 2018; 19(1):121.
PMID: 30594122
PMC: 6755564.
DOI: 10.1186/s10194-018-0951-2.
Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain.
Damien J, Colloca L, Bellei-Rodriguez C, Marchand S
Int Rev Neurobiol. 2018; 139:255-296.
PMID: 30146050
PMC: 6175288.
DOI: 10.1016/bs.irn.2018.07.024.
Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache.
Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M
Pain Res Treat. 2018; 2018:2516953.
PMID: 29862074
PMC: 5971252.
DOI: 10.1155/2018/2516953.
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V, Oakes T, Zhang Q, Ferguson M, Martinez J, Camporeale A
JAMA Neurol. 2017; 75(2):187-193.
PMID: 29255900
PMC: 5838630.
DOI: 10.1001/jamaneurol.2017.3859.
Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials.
Le K, Yu D, Wang J, Ali A, Guo Y
J Headache Pain. 2017; 18(1):69.
PMID: 28721545
PMC: 5515721.
DOI: 10.1186/s10194-017-0776-4.